Business Context and Reporting Period
Company: Alcon, Inc. (Swiss corporation, majority-owned subsidiary of Nestlé S.A.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three and six months ended June 30, 2006
Filing Date: July 25, 2006
Business Overview: Global leader in ophthalmic products, operating through two segments: Alcon United States and Alcon International. Product categories include pharmaceuticals, surgical equipment/devices, and consumer eye care.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended June 30, 2006 |
3 Months Ended June 30, 2005 |
6 Months Ended June 30, 2006 |
6 Months Ended June 30, 2005 |
|---|---|---|---|---|
| Sales | $1,310.8 | $1,172.0 | $2,467.9 | $2,242.5 |
| Gross Profit | $985.5 | $884.3 | $1,854.4 | $1,666.2 |
| Gross Margin % | 75.2% | 75.5% | 75.1% | 74.3% |
| Operating Income | $575.8 | $419.8 | $918.2 | $746.6 |
| Net Earnings | $465.6 | $325.0 | $761.3 | $574.5 |
| Diluted EPS | $1.50 | $1.04 | $2.45 | $1.85 |
| Cash from Operations (6mo) | $747.7 | $653.5 | ||
| Cash & Equivalents (Jun 30) | $1,237.6 | |||
| Total Debt (Jun 30) | $902.8 | |||
| Shareholders' Equity (Jun 30) | $2,739.6 |
Material Changes vs. Prior Period
- Revenue Growth: Global sales increased 11.8% (Q3) and 10.1% (YTD) compared to the prior year. Constant currency growth was 11.8% (Q3) and 11.1% (YTD), indicating organic volume and price growth.
- Profitability Surge: Net earnings rose 43.3% (Q3) and 32.5% (YTD). This was significantly driven by a $121.0 million pretax benefit in Q3 (and $119.0 million YTD) resulting from the settlement of patent litigation with Advanced Medical Optics, Inc. (AMO), which reduced previously accrued provisions.
- Accounting Change: Adoption of SFAS No. 123(R) for share-based compensation reduced net earnings by $12.5 million (Q3) and $33.6 million (YTD) due to the recognition of previously unrecognized compensation costs.
- Segment Performance:
- United States: Sales up 16.0% (Q3) and 13.5% (YTD). Operating income increased 23.1% (Q3) and 19.6% (YTD).
- International: Sales up 7.6% (Q3) and 6.6% (YTD). Operating income decreased 1.9% (Q3) but increased 4.3% (YTD), impacted by pricing pressure and facility repair costs in the UK.
- Product Drivers: Strong growth in AcrySof ReSTOR and IQ intraocular lenses, OPTI-FREE contact lens solutions (driven by competitor product withdrawal), and Systane artificial tears.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items:
- AMO Litigation Settlement: On July 10, 2006, Alcon settled all patent disputes with AMO for $121.0 million. Since $242.0 million was previously accrued, this resulted in a significant earnings benefit recognized in Q2 2006.
- Share-Based Compensation: The adoption of SFAS 123(R) on Jan 1, 2006, introduced new non-cash expenses that reduced operating income and net earnings compared to prior year reporting.
- Outlook & Guidance:
- Tax Rate: Management expects the full-year effective tax rate to be approximately 19% to 20%, assuming retroactive extension of the U.S. research and experimentation credit.
- Liquidity: The company expects to meet liquidity needs, including the $121.0 million litigation payment, through cash equivalents, short-term investments, and commercial paper facilities.
- Collaboration: Announced a co-promotion agreement with Eli Lilly for Arxxant (ruboxistaurin mesylate), a potential first oral medication for diabetic retinopathy, pending FDA approval.
- Risks:
- Market Risks: Exposure to foreign currency fluctuations (hedged via forwards/swaps) and interest rate changes (mostly floating rate debt).
- Regulatory: Dependence on FDA approvals and reimbursement policies (e.g., Medicare rules for intraocular lenses).
- Competition: Intense competition in ophthalmic markets; reliance on key products like Vigamox and AcrySof.
Investor Verification Checklist
- Sustainability of Earnings: Verify the extent to which Q2 2006 earnings were inflated by the one-time $121 million litigation benefit versus organic operational growth.
- Share-Based Compensation Impact: Assess the ongoing impact of SFAS 123(R) adoption on future margins, as full-year expense recognition is expected to be higher than prior years.
- Consumer Eye Care Volatility: Confirm if the surge in contact lens disinfectant sales (due to competitor product withdrawal) is sustainable or if it represents a temporary market share shift.
- Liquidity Position: Review the net cash position ($334.8 million) relative to the $121 million litigation payment and ongoing capital expenditures/dividend commitments.
- Reimbursement Policy: Monitor the stability of Medicare reimbursement rules for premium intraocular lenses (AcrySof ReSTOR/IQ), which are critical to surgical segment growth.